Your browser doesn't support javascript.
loading
Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50.
Attili, Ilaria; Valenza, Carmine; Santoro, Celeste; Antonarelli, Gabriele; Trillo Aliaga, Pamela; Del Signore, Ester; Catania, Chiara; Spitaleri, Gianluca; Passaro, Antonio; de Marinis, Filippo.
Afiliación
  • Attili I; Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan, Italy.
  • Valenza C; Division of New Drug Development, European Institute of Oncology IRCCS, Milan, Italy.
  • Santoro C; Università degli Studi di Milano, Department of Oncology and Hemato-Oncology, Milan, Italy.
  • Antonarelli G; Division of New Drug Development, European Institute of Oncology IRCCS, Milan, Italy.
  • Trillo Aliaga P; Università degli Studi di Milano, Department of Oncology and Hemato-Oncology, Milan, Italy.
  • Del Signore E; Division of New Drug Development, European Institute of Oncology IRCCS, Milan, Italy.
  • Catania C; Università degli Studi di Milano, Department of Oncology and Hemato-Oncology, Milan, Italy.
  • Spitaleri G; Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan, Italy.
  • Passaro A; Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan, Italy.
  • de Marinis F; Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan, Italy.
Front Oncol ; 12: 980765, 2022.
Article en En | MEDLINE | ID: mdl-36033444

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Suiza